Navigation Links
Soaring Prices Keep Leukemia Drugs From Patients, Experts Say
Date:4/26/2013

THURSDAY, April 25 (HealthDay News) -- Pricey cancer medications prevent many Americans with chronic myeloid leukemia (CML) from receiving lifesaving treatment, an international team of experts claims.

These drugs can cost more than $100,000 a year for patients with CML, once considered a death sentence but now highly treatable with ongoing treatment, according to a commentary penned by 120 specialists in more than 15 countries and published online April 25 in the journal Blood.

"Patients with CML have a much better outlook today than ever before, thanks to advances that have greatly improved survival rates. But these patients now face dire financial struggles as they try to maintain their treatment regimen with the drastically inflating cost of care," corresponding author Dr. Hagop Kantarjian, chairman of the leukemia department at the University of Texas MD Anderson Cancer Center in Houston, said in a journal news release.

"Since CML treatments must be taken on an ongoing basis, we are concerned that the surging prices are potentially harming patients," Kantarjian added.

In the United States, the CML survival rate is about 60 percent, significantly less than in Sweden, where survival odds are roughly 80 percent. That's likely because drug costs are managed in Sweden, the doctors noted.

Patients with other types of cancer who require ongoing treatment likely face the same barrier to treatment, Kantarjian added.

Eleven of 12 cancer drugs approved by the U.S. Food and Drug Administration in 2012 were priced above $100,000 a year, the report noted. And average monthly cancer drug prices have nearly doubled over the past decade -- from $5,000 a month to more than $10,000 a month, according to the news release.

Moreover, cancer care is a key factor in the massive cost of health care in the United States, estimated at 18 percent of the U.S. Gross Domestic Product, compared with less than 10 percent in much of Europe, the researchers added.

The drugs for CML include Gleevec from Novartis; Pfizer Inc.'s Bosulif; Sprycel from Bristol-Myers Squibb and Synribo from Teva.

How prices are set lies at the heart of the issue, according to the experts.

"In many cases, it makes sense to let the market govern the price; however, when a product is directly related to a patient's survival over a period of years, it is critical to set a price that allows companies to profit and ensures that patients can afford their treatment," said Kantarjian.

Drug makers argue that the stratospheric prices reflect the cost of research and development and the "value of a drug to patients," according to the New York Times.

In the Blood article, the authors noted that the reported cost of bringing a new cancer drug to market is roughly $1 billion, although not all experts agree on that high a figure.

Yet, Gleevec's sales were $4.7 billion in 2012 alone, the Times reported.

Noting the pricing and maintenance issue is "complex," Novartis said in a statement Thursday that it would "welcome the opportunity to be part of the dialogue."

This isn't the first time cancer specialists have banned together to oppose high drug prices, according to the Times. Last fall, doctors at Memorial Sloan-Kettering Cancer Center in New York City announced they wouldn't use the Sanofi colon cancer drug Zaltrap because it cost twice as much as another drug and wasn't an improvement. Subsequently, Sanofi cut the price of the drug in half.

More information

To learn about chronic myeloid leukemia, visit the U.S. National Cancer Institute.

--Margaret Farley Steele

SOURCE: American Society of Hematology, news release, April 25, 2013; New York Times


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. U.S. Diabetes Rates Soaring: CDC
2. Soaring U.S. Spinal Care Spending Due to Specialists: Study
3. Growth in Medical Payments per Claim in Pennsylvania Slowed in 2010 Due to Prices and Utilization of Nonhospital Services, Says New WCRI Study
4. Form W2C Software: EzW2Correction Updated For CPAs And Tax Filers By Halfpricesoft.com
5. Florida Businesses Can Switch To PC Payroll Software Easily With New EzPaycheck 2013 From Halfpricesoft.com
6. New 2013 EzPaycheck Payroll Software From Halfpricesoft.com Now Prints Company Logo On Paychecks
7. TENA Comfort Plus Incontinence Pads at Discounted Prices with Deliver Net Ltd
8. Feb 15 Approaching - Halfpricesoft.com Reminds Employers To Update 2013 Payroll Tax Tables
9. Easy Check Printing Software: Halfpricesoft.com Customized EzCheckPrinting For Small Businesses
10. W2 & 1099 Application: Halfpricesoft.com Customized EzW2 For New Employers
11. Small Business Users can Now Get EzCheckPrinting Software at $0 from Halfpricesoft.com
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Soaring Prices Keep Leukemia Drugs From Patients, Experts Say
(Date:5/3/2016)... ... May 04, 2016 , ... Safety ... global construction firms representing the Construction Industry Safety Initiative (CISI) and the Incident ... purpose: to inspire everyone in the industry to be leaders in safety. Statistics ...
(Date:5/3/2016)... ... May 04, 2016 , ... The National Association ... into its VIP Woman of the Year Circle. She is recognized with this prestigious ... professional women, boasting more than 850,000 members and over 200 operating Local Chapters. , ...
(Date:5/3/2016)... ... May 03, 2016 , ... According to an article ... issues related to medical care in the hospital setting, which include excessive wait ... hospital staff. Commenting on this article, the founder of House Call Doctor Los ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... 2016 Champion Award to Charles D. Pulido, R.Ph., Co-Founder of NCPDP and member ... Ph.D., Pharmacy Advisor and Health IT Specialist, Office of the National Coordinator for ...
(Date:5/3/2016)... Redondo Beach, CA (PRWEB) , ... May 03, 2016 , ... ... together online to help cancer patients and their families move toward recovery and is ... the focus of today's Dr. Carol Francis Talk Radio show considering medical ...
Breaking Medicine News(10 mins):
(Date:5/2/2016)... YORK , May 2, 2016 Kalorama ... EMR (Electronic Medical Records) market in a recent white ... sales, vendor switches, Increased physician usage, a growing market are ... were noted in Kalorama,s report EMR 2016: ... report marks Kalorama,s seventh complete study of the EMR ...
(Date:5/2/2016)... NEW YORK , May 2, 2016 /PRNewswire/ ... Series B financing of Graybug Vision, Inc. Graybug ... to developing therapies that may transform care for ... and glaucoma.  Graybug Vision,s technology was first developed ... out into a startup venture. ...
(Date:5/2/2016)... LAWRENCEVILLE, N.J. , May 2, 2016 /PRNewswire/ ... drug development company, today announced data from the ... dose escalating clinical trial (the OVATION Study) combining ... of care for the treatment of newly-diagnosed patients ... chemotherapy followed by interval debulking surgery.  In the ...
Breaking Medicine Technology: